| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2972680 | The Journal of Heart and Lung Transplantation | 2008 | 7 Pages |
Abstract
Indefinite GCV prophylaxis prevents CMV pneumonitis in 98% of LT recipients. Thirty-eight percent of patients discontinuing prophylaxis developed CMV pneumonitis, 50% of whom progressed to BOS within 1 year. Continuing ganciclovir prophylaxis indefinitely after lung transplantation should be considered.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Vincent G. MD, FACP, David MD, Meera R. MD, Brad MD, Stephanie G. RNC, BSN, Gisele A. RNC, BSN, Ryan W. BS, David E. MD, Gundeep S. MD,